[go: up one dir, main page]

MX2022000917A - Agonistas de receptores de cx3cr1 bicíclicos. - Google Patents

Agonistas de receptores de cx3cr1 bicíclicos.

Info

Publication number
MX2022000917A
MX2022000917A MX2022000917A MX2022000917A MX2022000917A MX 2022000917 A MX2022000917 A MX 2022000917A MX 2022000917 A MX2022000917 A MX 2022000917A MX 2022000917 A MX2022000917 A MX 2022000917A MX 2022000917 A MX2022000917 A MX 2022000917A
Authority
MX
Mexico
Prior art keywords
cx3cr1
bicyclic
receptor agonists
compounds
cx3cr1 receptor
Prior art date
Application number
MX2022000917A
Other languages
English (en)
Inventor
Paolo Pevarello
Philip Jones
William Ray
Mary Hamby
Yaima Luzardo Lightfoot
Russell Thomas
Chiara Liberati
Domenica Torino
Valentina Cusano
Francesco Piscitelli
Ali Yousif
Silvia Bovolenta
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2022000917A publication Critical patent/MX2022000917A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C07D333/80—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/32—All rings being cycloaliphatic the ring system containing at least eleven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En este documento se dan a conocer novedosos compuestos cicloalca[b]heteroarilo, que tienen propiedades agonistas del receptor CX3CR1/de fractalquina (CX3CR1), composiciones farmacéuticas que comprenden estos compuestos, procesos químicos para preparar estos compuestos, y su uso en el tratamiento o profilaxis de enfermedades asociadas con la actividad del receptor CX3CR1 en animales, en particular en humanos.
MX2022000917A 2019-07-23 2020-07-23 Agonistas de receptores de cx3cr1 bicíclicos. MX2022000917A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962877660P 2019-07-23 2019-07-23
PCT/US2020/043258 WO2021016449A1 (en) 2019-07-23 2020-07-23 Bicyclic cx3cr1 receptor agonists

Publications (1)

Publication Number Publication Date
MX2022000917A true MX2022000917A (es) 2022-04-07

Family

ID=74189124

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000917A MX2022000917A (es) 2019-07-23 2020-07-23 Agonistas de receptores de cx3cr1 bicíclicos.

Country Status (11)

Country Link
US (3) US11155538B2 (es)
EP (1) EP4003972A4 (es)
JP (1) JP2022541627A (es)
KR (1) KR20220090492A (es)
CN (1) CN114929681B (es)
AU (1) AU2020316080A1 (es)
BR (1) BR112022001184A2 (es)
CA (1) CA3148454A1 (es)
IL (1) IL290024A (es)
MX (1) MX2022000917A (es)
WO (1) WO2021016449A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114929681B (zh) 2019-07-23 2024-05-14 德州大学系统董事会 二环cx3cr1受体激动剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401969D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidine derivatives
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AR075402A1 (es) * 2009-02-13 2011-03-30 Sanofi Aventis Derivados heterociclicos oxigenados y/o nitrogenados de tetrahidronaftaleno, medicamentos que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad,entre otros.
WO2012012322A1 (en) * 2010-07-19 2012-01-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012078633A2 (en) * 2010-12-07 2012-06-14 Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene Methods of inhibiting metastasis from cancer
CN104744451A (zh) 2013-12-30 2015-07-01 中国科学院上海药物研究所 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途
TR201910305T4 (tr) * 2014-04-17 2019-07-22 Pasteur Institut Korea Viral enfeksiyonları tedavi etmek için bileşikler.
US11267817B2 (en) 2017-05-02 2022-03-08 Drexel University Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists
CN114929681B (zh) 2019-07-23 2024-05-14 德州大学系统董事会 二环cx3cr1受体激动剂

Also Published As

Publication number Publication date
US11958839B2 (en) 2024-04-16
KR20220090492A (ko) 2022-06-29
US20210024510A1 (en) 2021-01-28
EP4003972A4 (en) 2023-07-12
JP2022541627A (ja) 2022-09-26
US20220259191A1 (en) 2022-08-18
US12258337B2 (en) 2025-03-25
US11155538B2 (en) 2021-10-26
AU2020316080A1 (en) 2022-03-03
CN114929681A (zh) 2022-08-19
BR112022001184A2 (pt) 2022-03-15
IL290024A (en) 2022-03-01
CA3148454A1 (en) 2021-01-28
CN114929681B (zh) 2024-05-14
EP4003972A1 (en) 2022-06-01
WO2021016449A1 (en) 2021-01-28
US20240150332A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
CL2022000998A1 (es) Inhibidores de las cinasas raf
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
CL2021000387A1 (es) Compuestos de anillo fusionado
CO2018010966A2 (es) Nuevos derivados de pirazolopirimidina
AR119389A1 (es) Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
MX2023001647A (es) Sulfonilureas y compuestos relacionados y uso de estos.
CL2017002650A1 (es) Compuestos novedosos
CL2016002148A1 (es) Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
UY38226A (es) Nuevos derivados de quinolina
MX2019009126A (es) Composiciones y metodos para la liberacion prolongada de antagonistas de la hormona liberadora de gonadotropina (gnrh).
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CO2019011546A2 (es) Compuestos y métodos para el tratamiento de enfermedades parasitarias
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
CO2021016433A2 (es) Derivados heterocíclicos condensados
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
BR112016030730A8 (pt) composto
CO2024009144A2 (es) Inhibidores de cinasa met
MX2024003107A (es) Agonistas de ahr.
BR112017020374A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
MX388815B (es) Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia.
MX2022000917A (es) Agonistas de receptores de cx3cr1 bicíclicos.
DOP2022000203A (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad antagonista gpr52
EA201890847A1 (ru) Композиции и способы ингибирования бета-лактамазы